Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.
Viruses
; 13(3)2021 03 23.
Article
in English
| MEDLINE | ID: covidwho-1154526
ABSTRACT
The etiological agent of the COVID-19 pandemic is SARS-CoV-2. As a member of the Coronaviridae, the enveloped pathogen has several membrane proteins, of which two, E and 3a, were suggested to function as ion channels. In an effort to increase our treatment options, alongside providing new research tools, we have sought to inhibit the 3a channel by targeted drug repurposing. To that end, using three bacteria-based assays, we screened a library of 2839 approved-for-human-use drugs and identified the following potential channel-blockers Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine and Fludarabine. The stage is now set for examining the activity of these compounds in detailed electrophysiological studies and their impact on the whole virus with appropriate biosafety measures.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Viral Envelope Proteins
/
Drug Repositioning
/
Viroporin Proteins
/
SARS-CoV-2
/
COVID-19
Type of study:
Etiology study
/
Prognostic study
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
V13030532
Similar
MEDLINE
...
LILACS
LIS